Dry Powder Inhalers: Key Considerations for Combination Product Development
Sponsored Content
Dry powder inhalers (DPIs) are an important delivery technology for inhaled medicines in both respiratory and non-respiratory disease areas. Andreas Meliniotis, director of device development at Vectura, helps navigate the complex area of DPI product development and highlights the key considerations for both novel- and generic-drug programs. Live: Wednesday, Jun. 24, 2020 at 11am EDT |8am PDT |4pm BST |5pm CEST On demand available after final airing Jun. 24, 2021 Register free
Register free: http://www.pharmtech.com/pt_w/key_considerations
Event Overview:
Dry powder inhalers are an important technology for the delivery of therapies for both respiratory and non-respiratory disease areas. The development of such drug-device combination products is highly complex and several factors can have a significant impact on the success of the program. This webcast discusses the key considerations to reduce risk when developing a DPI product from early clinical trials through to scale-up, and provides insights for both novel and generic development programs.
Key Learning Objectives:
- Understanding different options for dry powder inhaler technology
- Key considerations for DPI product development
- Manufacturing strategies for seamless transition and scalability from lab to commercial scale
- Relevant regulatory guidance and risk-based approaches to process development and device design
- Device strategies for novel and generic inhaled development programs
Speaker: Andreas Meliniotis, Director, Device Development, Vectura Group plc.
Time and Date: Wednesday, Jun. 24, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after final airing Jun. 24, 2021
Sponsor: Vectura Group plc
Register free: http://www.pharmtech.com/pt_w/key_considerations